Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Vertex Buys 2 Hepatitis Drugs For $376.8 million

By Pharmaceutical Processing | March 4, 2009

CAMBRIDGE, Mass. (AP) — Vertex Pharmaceuticals Inc. said Tuesday it bought two hepatitis C drug candidates from ViroChem Pharma Inc., and plans to test the drugs in combination with its own drug candidate telaprevir. Vertex will pay ViroChem $100 million in cash for the drugs, along with 9.9 million shares of its stock. The company’s shares closed at $27.96 Tuesday, implying a value of $276.8 million for the stock and a total value of $376.8 million for the drugs. Based on laboratory tests, Vertex said a combination of telaprevir and the two drugs might be more effective against hepatitis C than telaprevir alone. The company said it plans to start a clinical study combining telaprevir with one of the ViroChem drugs in the second half of 2009. Hepatitis C is a viral liver disease that causes inflammation and can cause liver failure. Vertex is conducting late stage trials of telaprevir, but the ViroChem drugs are in early clinical development.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE